IPF
Clinical trials for IPF explained in plain language.
Never miss a new study
Get alerted when new IPF trials appear
Sign up with your email to follow new studies for IPF, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for scarred lungs: experimental drug enters patient testing
Disease control Recruiting nowThis study is testing a new oral drug called SB17170 for people with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. About 30 patients will take either the drug or a placebo pill daily for 12 weeks to see if it helps slow the decline in lung function and imp…
Matched conditions: IPF
Phase: PHASE2 • Sponsor: SPARK Biopharma • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
First human test for new IPF inhaler begins
Disease control Recruiting nowThis is the first study in people to test the safety of an experimental inhaled medicine called AGMB-447 for idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. The study will enroll healthy volunteers and people with IPF to see how their bodies handle single an…
Matched conditions: IPF
Phase: PHASE1 • Sponsor: Agomab Spain S.L. • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC
-
Can video calls and exercise videos help people breathe easier?
Symptom relief Recruiting nowThis study is testing if two different types of home exercise programs can help people with idiopathic pulmonary fibrosis (IPF), a serious lung scarring disease. Researchers will compare a program with live video sessions with a therapist to one using pre-recorded exercise videos…
Matched conditions: IPF
Phase: NA • Sponsor: Istanbul Medipol University Hospital • Aim: Symptom relief
Last updated Apr 01, 2026 14:43 UTC
-
First human test for new lung disease tablet begins
Knowledge-focused Recruiting nowThis is the first study in humans to test the safety and how the body processes a new tablet called HW241045. The trial involves 56 healthy volunteers who will receive either the tablet or a placebo. Researchers will monitor for side effects and measure how the drug moves through…
Matched conditions: IPF
Phase: PHASE1 • Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:28 UTC